These stocks have an unusual volume in today's session
By Mill Chart
Last update: Mar 26, 2024
Let's explore the current happenings on the US markets on Tuesday. Below, you'll find the stocks exhibiting unusual volume in today's session.
Today's unusual volume stocks
| Ticker | Change | Comment |
|---|---|---|
| XTLB | 6.04% | Today's trading session witnessed an unusual volume of 1.16M shares for XTL BIOPHARMACEUTICALS-ADR (NASDAQ:XTLB). The price of NASDAQ:XTLB has increased by 6.04%, indicating upward momentum in the market. This volume is 33.56% above the average 50 day volume. |
| IDN | -11.48% | Today's trading session witnessed an unusual volume of 963.26K shares for INTELLICHECK INC (NASDAQ:IDN). NASDAQ:IDN is showing a decline of 11.48% in today's trading. This is 77.96% above the average daily volume of the last 50 days. |
| FLGC | 14.28% | The stock of FLORA GROWTH CORP (NASDAQ:FLGC) has caught attention with a significant volume of 2.84M shares today. NASDAQ:FLGC is experiencing an advancement of 14.28% in its share price today. This volume is 434.0% above the average 50 day volume. |
| YCBD | 23.04% | CBDMD INC (NYSEARCA:YCBD) has an unusual volume of 1.48M shares. NYSEARCA:YCBD is advancing 23.04% today. This is 526.0% above the average daily volume of the last 50 days. |
| CZOO | 52.35% | CAZOO GROUP LTD's (NYSE:CZOO) traded a high volume of 7.76M shares. NYSE:CZOO is advancing 52.35% today. This is 2.0K% above the average daily volume of the last 50 days. |
| SLRX | -0.47% | 234.12K shares of SALARIUS PHARMACEUTICALS INC (NASDAQ:SLRX) have been traded so far today. The share price experienced a decrease of 0.47%. This is 90.27% above the average daily volume of the last 50 days. |
| EGOX | -30.06% | The trading activity for NEXT.E.GO NV (NASDAQ:EGOX) has surged with a volume of 28.39M shares today. This decline in share price leads to a decrease of 30.06%. This volume is 218.0% above the average 50 day volume. |
| ISPC | -4.02% | The trading volume of ISPECIMEN INC (NASDAQ:ISPC) today is 330.23K shares, which is considered unusual. NASDAQ:ISPC is showing a decline of 4.02% in today's trading. The average volume measured over 50 days is 137.02K, so this is 141.0% above the average volume. |
| LXEH | -13.73% | LIXIANG EDUCATION HOLDIN-ADR's (NASDAQ:LXEH) traded a high volume of 1.16M shares. The current market conditions have led to a price decrease of 13.73% for NASDAQ:LXEH. This is 44.45% above the average daily volume of the last 50 days. |
| MGAM | -15.04% | The stock of MOBILE GLOBAL ESPORTS INC (NASDAQ:MGAM) has caught attention with a significant volume of 888.09K shares today. The share price experienced a decrease of 15.04%. In comparison to the average daily volume of the last 50 days, the current volume is 225.0% above. This suggests a notable change in trading activity. |
To see the full list of unusual volume stocks you can use our unusual volume stocks screener.
SALARIUS PHARMACEUTICALS INC
NASDAQ:SLRX (4/26/2024, 7:16:30 PM)
After market: 0.4771 -0.02 (-3.64%)0.4951
0 (-0.78%)
SLRX News
a month ago - BusinessInsiderWhy Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving PremarketShares of Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) rose sharply in today’s pre-market trading following fourth-quarter results.
a month ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe are starting off the day with a breakdown of the biggest pre-market stock movers that traders need to know about on Monday morning.
a month ago - InvestorPlaceSLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q4 2023SLRX stock results show that Salarius Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023.
a month ago - BusinessInsiderSLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q4 2023InvestorPlace - Stock Market News, Stock Advice & Trading Tips Salarius Pharmaceuticals (NASDAQ:SLRX) just reported results for the fourth qua...
Patient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of Seclidemstat in Combination with Azacitidine to Treat Hematologic...
2 months ago - Seeking AlphaSalarius's CEO David Arthur steps down (NASDAQ:SLRX)Salarius Pharmaceuticals announces cost-savings measures including CEO transition, reduced expenses, and compensation, to support ongoing clinical trials.
3 months ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time for a breakdown of the biggest pre-market stock movers for Wednesday morning as we check out all of the latest news today!
Additional Ewing Sarcoma Patient in Company’s Phase 1/2 Sarcoma Trial Achieves Partial Response; Objective Response Rate Among First-Relapse Ewing Patients...
